Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
06618 JD HEALTH
RTNominal up25.800 +1.000 (+4.032%)
Research Report

14/01/2021 15:44

{I-bank focus}Jefferies starts JD Health (06618) at HK$184

[ET Net News Agency, 14 January 2021] Jefferies Research initiated coverage on JD
Health International (06618) with a "buy" rating and a price target of HK$184.
The research house said JD Health is a multitudinal play involving some of the
fastest-growing sectors in China: healthcare, internet, and consumer while giving exposure
to digital health and drugstores.
More importantly, it is already profitable and is gaining market share in a growing pie,
riding on the rising online penetration rate of drugstores backed by a margin expansion
story.
Jefferies projected 2019-22 sales and adjusted net profit CAGR of 49% and 26%. It
expects the top line to reach RMB19bn/RMB25bn/RMB36bn and the adjusted bottom line to
reach RMB322mn/RMB420mn/RMB692mn in 2020/21/22. (KL)

Back to Research Report

Remark: Real time quote last updated: 26/04/2024 12:57
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.